摘要
目的分析利培酮联合氯氮平在难治性精神分裂症患者中的临床应用效果。方法随机选择2018年1月—2021年12月太仓市第三人民医院就诊的60例精神分裂症患者为研究对象,按照随机数列将其分成对照组与研究组,各30例。对照组单独应用氯氮平给予治疗,研究组在对照组基础上增用利培酮进行治疗。研究共进行3个月,分别对比基线以及3个月后蒙特利尔认知评估量表(MoCA)、社会功能缺陷筛选量表(SDSS)评分,对比治疗前后不同时段的精神病量表(BPRS)各因子评分,同时统计用药周期内的药物不良反应发生情况。结果治疗前,两组MoCA、SDSS评分比较,差异无统计学意义(P>0.05);治疗后,研究组MoCA评分高于对照组,SDSS评分低于对照组,差异有统计学意义(P<0.05)。两组在治疗后1个月、治疗后3个月BPRS各项评分均下降,研究组BPRS各项评分明显低于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率为13.33%低于对照组的16.66%,差异无统计学意义(χ^(2)=0.000,P>0.05)。研究组临床总有效率为96.66%明显高于对照组的73.33%,差异有统计学意义(P<0.05)。结论难治性精神分裂症患者应用利培酮联合氯氮平能有效改善患者的精神病性症状,控制病情发展,且联合用药下并未增加药物不良反应,能取得较为理想的临床效果。
Objective Analyze the clinical application effect of risperidone combined with clozapine in patients with refractory schizophrenia.Methods 60 patients with schizophrenia who visited the Third People's Hospital of Taicang City from January 2018 to December 2021 were randomly selected as the study subjects.They were randomly divided into a control group and a study group,with 30 patients in each group.The control group was treated with clozapine alone,while the study group was treated with risperidone in addition to the control group.The study was conducted for a total of 3 months,comparing the baseline and 3-month post Montreal Cognitive Assessment Scale(MoCA)and Social Deficiency Screening Scale(SDSS)scores,comparing the factor scores of the Mental Disorder Scale(BPRS)before and after treatment at different time periods,and calculating the incidence of drug adverse reactions during the medication cycle.Results Before treatment,there was no statistically significant difference in MoCA and SDSS scores between the two groups(P>0.05);after treatment,the MoCA score of the study group was higher than that of the control group,while the SDSS score was lower than that of the control group,and the difference was statistically significant(P<0.05).The BPRS scores of the two groups decreased at 1 month,and 3 months after treatment.The BPRS scores of the study group were significantly lower than those of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 13.33%lower than that in the control group,which was 16.66%,and the difference was not statistically significant(χ^(2)=0.000,P>0.05).The total clinical effectiverate of the study group was 96.66%,which was significantly higher than the control group's 73.33%,and the difference was statistically significant(P<0.05).Conclusion The combination of risperidone and clozapine can effectivelyimprove the psychiatric symptoms of patients with refractory schizophrenia,control the progression of the condition,and achieve ideal clinical results without increasing adverse drug reactions.
作者
吴爱菊
WU Aiju(Department of Psychiatry,Taicang Third People's Hospital,Taicang,Jiangsu Province,215400 China)
出处
《中外医疗》
2023年第12期152-156,共5页
China & Foreign Medical Treatment
关键词
难治性精神分裂症
利培酮
氯氮平
联合治疗
临床疗效
Refractory schizophrenia
Risperidone
Clozapine
Combination therapy
Clinical efficacy
